Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Owing to the rarity of adrenocortical carcinoma (ACC) no prognostic markers have been established beyond stage and resection status. Accelerated glycolysis is a characteristic feature of cancer cells and in a variety of tumour entities key factors in glucose metabolism like glucose transporter 1 and 3 (GLUT1 and -3), transketolase like-1 enzyme (TKTL1) and pyruvate kinase type M2 (M2-PK) are overexpressed and of prognostic value. Therefore, we investigated the role of these factors in ACC. Immunohistochemical analysis was performed on tissue microarrays of paraffin-embedded tissue samples from 167 ACCs, 15 adrenal adenomas and 4 normal adrenal glands. Expression was correlated with baseline parameters and clinical outcome. GLUT1 and -3 were expressed in 33 and 17% of ACC samples respectively, but in none of the benign tumours or normal adrenals glands. By contrast, TKTL1 and M2-PK were detectable in all benign tissues and the vast majority of ACCs. GLUT1 expression was strongly associated with prognosis in univariate and multivariate analysis (P<0.01), whereas GLUT3, TKTL1 and M2-PK did not correlate with clinical outcome. Patients with strong GLUT1 staining showed a considerably higher overall mortality (hazard ratio (HR) 6.34 (95% confidence interval 3.10–12.90) compared with patients with no GLUT1 staining. When analysing patients in their early stages and advanced disease separately, similar results were obtained. HR for survival was 5.31 (1.80–15.62) in patients with metatastic ACC and in patients after radical resection the HR for disease-free survival was 6.10 (2.16–16.94). In conclusion, GLUT1 is a highly promising stage-independent, prognostic marker in ACC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathologic features of prognostic significance in adrenocortical carcinoma
Weiss, L. M., Medeiros, L. J., & Vickery, A. L. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198903000-00004 · Cited by 818 · cited 1×
“All histological diagnoses were confirmed by the reference pathologist of the German ACC Registry (Wolfgang Saeger, Hamburg, Germany) and malignancy was established by a Weiss score R3 (Weiss et al. 1989).”
MethodPyruvate kinase type M2 and its role in tumor growth and spreading
Mazurek, S., Boschek, C. B., Hugo, F., & Eigenbrodt, E. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.04.009 · Cited by 812
Adrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Self-citationFassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695
Self-citationManagement of patients with adrenal cancer: recommendations of an international consensus conference
Schteingart, D. E., Doherty, G. M., Gauger, P. G., Giordano, T. J., Hammer, G. D., Korobkin, M., & Worden, F. P. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01029 · Cited by 421 · cited 2×
“The precise pathogenesis of ACC is still poorly understood and due to the rarity of the disease prognostic assessment and treatment strategies are not well standardised (Schteingart et al. 2005).”
BackgroundBlood—Brain Barrier Glucose Transporter: Effects of Hypo‐ and Hyperglycemia Revisited
Simpson, I. A., Appel, N. M., Hokari, M., Oki, J., Holman, G. D., Maher, F., Koehler‐Stec, E. M., Vannucci, S. J., & Smith, Q. R. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720238.x · Cited by 304
Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma
Fassnacht, M., Hahner, S., Polat, B., Koschker, A.-C., Kenn, W., Flentje, M., & Allolio, B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1007 · Cited by 259 · cited 2×
“Many patients present with locally advanced or metastatic disease and up to 85% of patients with radically resected tumours relapse (Allolio and Fassnacht, 2006; Fassnacht et al., 2006).”
BackgroundSelf-citationPrognostic parameters of metastatic adrenocortical carcinoma
Assié, G., Antoni, G., Tissier, F., Caillou, B., Abiven, G., Gicquel, C., Leboulleux, S., Travagli, J.-P., Dromain, C., Bertagna, X., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0706 · Cited by 236 · cited 4×
“Similar results were found by Assie et al. (2007) analysing 44 selected patients with metastasised ACC.”
BackgroundResultInfluentialManagement of adrenocortical carcinoma
Allolio, B., Hahner, S., Weismann, D., & Fassnacht, M. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01881.x · Cited by 214
Self-citation
Cited by
Anticancer Targets in the Glycolytic Metabolism of Tumors: A Comprehensive Review
Porporato, P. E., Dhup, S., Dadhich, R. K., Copetti, T., & Sonveaux, P. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00049 · Cited by 425
Update in Adrenocortical Carcinoma
Fassnacht, M., Kroiss, M., & Allolio, B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3020 · Cited by 414
Self-citationGlucose Conjugation for the Specific Targeting and Treatment of Cancer
Calvaresi, E. C., & Hergenrother, P. J. (2013) · Chemical Science · doi:10.1039/c3sc22205e · Cited by 398
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396
“In addition, overexpression of matrix metalloproteinase 2 and the glucose transporter GLUT1 has been linked to reduced survival”
BackgroundSelf-citationHypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters
Marchiq, I., & Pouysségur, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1307-x · Cited by 300
“Thus glucose transporters and downstream glycolytic enzymes are overexpressed in more than 70 % of cancers [23, 24].”
BackgroundGaujoux, S., Grabar, S., Fassnacht, M., Ragazzon, B., Launay, P., Libé, R., Chokri, I., Audebourg, A., Royer, B., Sbiera, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2006 · Cited by 146
Self-citationVolante, M., Terzolo, M., Fassnacht, M., Rapa, I., Germano, A., Sbiera, S., Daffara, F., Sperone, P., Scagliotti, G., Allolio, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2692 · Cited by 69
Self-citationPapotti, M., Duregon, E., Volante, M., & McNicol, A. M. (2014) · Endocrine Pathology · doi:10.1007/s12022-013-9291-6 · Cited by 33
Hommell-Fontaine, J., Isaac, S., Passot, G., Decullier, E., Traverse-Glehen, A., Cotte, E., You, B., Mohamed, F., Gilly, F. N., Glehen, O., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3077-4 · Cited by 23
Metadata
- Authors
- Fenske, W., Völker, H.-U., Adam, P., Hahner, S., Johanssen, S., Wortmann, S., Schmidt, M., Morcos, M., Müller-Hermelink, H.-K., Allolio, B., & Fassnacht, M.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2009-09
- Volume
- 16
- Issue
- 3
- Pages
- 919-928
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2170646689
- Cited by
- 84
- References
- 9
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.